Gentamycin Sulfate Injection

This product is an aminoglycoside antibiotic. It has good antibacterial effects on various Gram-negative and Gram-positive bacteria, and has good antibacterial effects on various Enterobacteriaceae such as Escherichia coli, Klebsiella, Proteus, Salmonella, Shigella, Enterobacter, Serratia and Pseudomonas aeruginosa. Neisseria and Haemophilus influenzae are moderately sensitive to this product. It also has a certain effect on Brucella, Yersinia pestis, Acinetobacter and Campylobacter fetus. It has a good antibacterial effect on about 80% of methicillin-sensitive strains of Staphylococcus (including Staphylococcus aureus and coagulase-negative Staphylococci), but methicillin-resistant strains are mostly resistant to this product. It has a poor effect on Streptococcus and Streptococcus pneumoniae, and Enterococcus is mostly resistant to this product. When this product is used in combination with beta-lactams, most of them can obtain a synergistic antibacterial effect. The mechanism of action of this product is to bind to the 30S subunit of bacterial ribosomes and inhibit the synthesis of bacterial proteins. In recent years, the number of gram-negative bacteria resistant to gentamicin has increased significantly.

The main ingredient of this product is gentamicin sulfate, which is a multi-component antibiotic containing components such as C1, C1a, C2a, and C2.

This product is a colorless or almost colorless clear liquid.

1. It is suitable for the treatment of severe infections caused by sensitive Gram-negative bacilli, such as Escherichia coli, Klebsiella, Enterobacter, Proteus, Serratia, Pseudomonas aeruginosa, and methicillin-sensitive strains of Staphylococcus, such as sepsis, lower respiratory tract infection, intestinal infection, pelvic infection, abdominal infection, skin and soft tissue infection, complicated urinary tract infection, etc. It should be used in combination with anti-anaerobic drugs for the treatment of abdominal and pelvic infections. In clinical practice, gentamicin is often used in combination with other antibacterial drugs. It can be used in combination with penicillin (or ampicillin) to treat enterococcal infections. 2. When used for central nervous system infections caused by sensitive bacteria, such as meningitis and ventriculitis, this product can be used for intrathecal injection as an auxiliary treatment.

Intramuscular injection or intravenous drip after dilution: 80 mg (80,000 units) once, 2 to 3 times a day with an interval of 8 hours. Children should take 3 to 5 mg (3,000 to 5,000 units) per kilogram of body weight per day, divided into 2 to 3 doses.

1. During medication, ototoxic reactions such as hearing loss, tinnitus, or a feeling of fullness in the ears may occur. When vestibular function is affected, unsteady gait and dizziness may occur. Nephrotoxic reactions such as hematuria, a significant decrease in the frequency of urination or urine volume, loss of appetite, and extreme thirst may also occur. Those with a lower incidence include dyspnea, drowsiness, weakness, etc. caused by neuromuscular blockade or nephrotoxicity. Occasionally, there may be rash, nausea, vomiting, decreased liver function, leukopenia, granulocytopenia, anemia, hypotension, etc. 2. A small number of patients may experience ototoxic symptoms such as hearing loss, tinnitus, or a feeling of fullness in the ears after discontinuation of the drug, which should be paid attention to. 3. Systemic administration combined with intrathecal injection may cause leg cramps, rash, fever, and systemic spasms.

Patients who are allergic to this product or other aminoglycosides are contraindicated.

1. When used in combination with other aminoglycosides or when used topically or systemically successively, it may increase the possibility of producing ototoxicity, nephrotoxicity and neuromuscular blocking effects. 2. When used in combination with neuromuscular blockers, it may aggravate neuromuscular blocking effects, leading to symptoms such as muscle weakness and respiratory depression. 3. When used in combination with capreomycin, cisplatin, ethacrynic acid, furosemide or vancomycin (or norvancomycin), or when used topically or systemically successively, it may increase ototoxicity and nephrotoxicity. 4. When used topically or systemically with cephalothin or cefazolin, it may increase nephrotoxicity. 5. When used in combination with polymyxin injections or when used topically or systemically successively, it may increase nephrotoxicity and neuromuscular blocking effects. 6. Other nephrotoxic and ototoxic drugs should not be used in combination with this product or when used topically successively, so as not to aggravate nephrotoxicity or ototoxicity. 7. When aminoglycosides and beta-lactams (cephalosporins and penicillins) are mixed, they may lead to mutual inactivation. When this product is used in combination with the above-mentioned antibiotics, it must be dripped in separate bottles. This product should not be infused in the same bottle with other drugs.

Keep tightly closed in a cool, dark place.

2ml: 80,000 units

Wuhan Aimin Pharmaceutical Co., Ltd.

• Founded in:

  1990-03-17

• Address:

  No. 10, Chuangye Avenue, Gedian Economic Development Zone, Ezhou City, Hubei Province

• Tax NO.:

  91420700177707714R

• Registered Funds:

  100.52 million yuan

• Website:

  Log in to view

• Email:

  Log in to view